BFRIHealthcare · Drug Manufacturers - Specialty & GenericBFRI Stock Forecast: Biofrontera, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Biofrontera, Inc. hold a median 12-month price target of $5.88 — +393.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 1 Aug 2026 — in the upper half.
BFRI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Biofrontera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Biofrontera, Inc. — and when they’d sell — is the membership.
BFRI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BFRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +393.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | Benchmark | Downgrade | Speculative Buy | $3.00 |
| 19 May 2025 | Benchmark | Maintains | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 31 Aug 2023 | Benchmark | Reiterates | Buy | — |
| 5 July 2023 | Benchmark | Maintains | Buy | $140 → $18 |
| 15 May 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 9 Mar 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 31 Jan 2023 | Benchmark | Reiterates | Buy | $11 → $7.00 |
| 15 Dec 2021 | Benchmark | Initiates | Buy | $11 |
| 24 Nov 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BFRI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Biofrontera, Inc. (BFRI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.9×
- Price / sales
- 0.3×
- Price / book
- 2.3×
- EV / EBITDA
- −1.6×
Cheaper than 70% of US stocks
Cheaper than 88% of US stocks
Cheaper than 42% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- 17.4%
- Earnings growth (YoY)
- —
- Gross margin
- 79.0%
- Operating margin
- −39.0%
- Net margin
- −25.7%
Higher than 69% of US stocks
Higher than 90% of US stocks
Higher than 19% of US stocks
Higher than 14% of US stocks
- Return on equity
- −339.0%
- Return on assets
- −32.4%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BFRI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BFRI appears on the weeks it earns a place.
Frequently asked questions about BFRI stock
What is the BFRI stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Biofrontera, Inc. have a median 12-month price target of $5.88, with estimates ranging from $2.75 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BFRI stock a buy right now?
Of the 2 analysts covering Biofrontera, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biofrontera, Inc. 55 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BFRI?
As at 1 Aug 2026, Biofrontera, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
Will BFRI stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +393.7% from the last close, and Ticker Nerd's factor model ranks Biofrontera, Inc. 55 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BFRI stock forecast for 2030?
No analyst covering Biofrontera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BFRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $9 over the next 12 months.
How has BFRI stock performed over the past year?
Biofrontera, Inc. returned +14.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Biofrontera, Inc. do?
Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products.
About Biofrontera, Inc.
Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products. Its primary aim is to address unmet needs in the treatment of skin diseases, with a particular emphasis on dermatology, represented by its flagship product, Ameluz. This prescription medication is used in photodynamic therapy to treat actinic keratosis and basal cell carcinoma, offering a non-invasive option for patients. Biofrontera Inc. also owns a range of other topical dermatology treatments and has made strategic partnerships to enhance its market presence. By driving innovation in skin health solutions, the company impacts the healthcare industry, notably benefiting dermatologists and their patients. Based in Woburn, Massachusetts, Biofrontera plays a significant role in dermatological therapeutics, striving to expand its product portfolio through continuous research and development. Its dedication to providing effective solutions for skin conditions aligns with broader trends in personalized and targeted healthcare, making it a notable player in the specialty pharma space.
CEO Dr. Hermann Luebbert Ph.D. · 84 employees · United States · https://www.biofrontera-us.com